Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) EPS (Weighted Average and Diluted) (2020 - 2024)

SELLAS Life Sciences (SLS) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.08 as the latest value for Q4 2024.

  • Quarterly EPS (Weighted Average and Diluted) rose 68.0% to -$0.08 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$0.52 through Dec 2024, up 61.76% year-over-year, with the annual reading at -$0.25 for FY2025, 50.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2024 was -$0.08 at SELLAS Life Sciences, up from -$0.1 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.08 in Q4 2024, with the low at -$1.05 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.36, with a median of -$0.33 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 556.25% in 2022, then skyrocketed 69.7% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.28 in 2020, then crashed by 50.0% to -$0.42 in 2021, then dropped by 2.38% to -$0.43 in 2022, then surged by 41.86% to -$0.25 in 2023, then skyrocketed by 68.0% to -$0.08 in 2024.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.08, -$0.1, and -$0.13 for Q4 2024, Q3 2024, and Q2 2024 respectively.